Cite
APA Citation
Schuler, M., Paz-Ares, L., Sequist, L., Tan, E., Mok, T., Hirsh, V., O'Byrne, K., Zhang, L., Yamamoto, N., Boyer, M., Shah, R., Bennouna, J., Dickgreber, N., De Grève, J., Love, J., Märten, A., Fan, J., Ehrnrooth, E., Park, K., & Yang, J. (n.d.). first-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials. European journal of cancer, 72, S176–S177. http://access.bl.uk/ark:/81055/vdc_100041521804.0x000049